| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 具有含氮取代基的键合聚合物的多环芳烃 | CN201280054684.2 | 2012-10-30 | CN103998541B | 2015-11-25 | C·巴斯吉耶; P·维斯 |
| 本发明涉及通式(1)键合聚合物的多环芳烃化合物，其中P表示具有至少三个包含任选取代苯环的重复单元的聚合结构部分；Q表示二萘嵌苯、四萘嵌三苯或三萘嵌二苯结构部分；Y选自：(i)卤素和(ii)具有3至约8个环成员且通过N原子结合在Q上的任选取代N-杂脂环族基团，条件是至少一个Y表示(ii)；x表示1-4的整数；w表示1-4的整数。本发明进一步涉及制备这种化合物的方法，及其在可特别用于制备标识或安全特征的印刷油墨组合物中的用途。(P—O)x—Q—(Y)w (1)。 | ||||||
| 2 | 聚碳酸酯‑聚酯组合物及制品 | CN201580040282.0 | 2015-07-08 | CN106574102A | 2017-04-19 | 库马尔·帕里马尔; 萨拉·格里斯哈伯 |
| 组合物包含特定量的具有对苯二甲酸1,4‑环己烷二亚甲基酯重复单元的聚酯、不含卤素的芳香族聚碳酸酯、溴化芳香族聚碳酸酯和未取代或取代的C2‑C18‑烃基磺酸盐。相对于不含所述磺酸盐的相应的组合物，所述组合物表现阻燃性和透明性的改善的平衡。所述组合物可以用于制造受益于其透明性和阻燃性的制品。 | ||||||
| 3 | 具有含氮取代基的键合聚合物的多环芳烃 | CN201280054684.2 | 2012-10-30 | CN103998541A | 2014-08-20 | C·巴斯吉耶; P·维斯 |
| 本发明涉及通式(1)键合聚合物的多环芳烃化合物，其中P表示具有至少三个包含任选取代苯环的重复单元的聚合结构部分；Q表示二萘嵌苯、四萘嵌三苯或三萘嵌二苯结构部分；Y选自：(i)卤素和(ii)具有3至约8个环成员且通过N原子结合在Q上的任选取代N-杂脂环族基团，条件是至少一个Y表示(ii)；x表示1-4的整数；w表示1-4的整数。本发明进一步涉及制备这种化合物的方法，及其在可特别用于制备标识或安全特征的印刷油墨组合物中的用途。(P—O)x—Q—(Y)w (1) | ||||||
| 4 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | EP15840612.4 | 2015-09-10 | EP3191449A1 | 2017-07-19 | CHEUNG, Mui; DEMARTINO, Michael P.; EIDAM, Hilary Schenck; GUAN, Huiping Amy; QIN, Donghui; WU, Chengde; GONG, Zhen; YANG, Haiying; YU, Haiyu; ZHANG, Zhiliu |
| This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity. | ||||||
| 5 | SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF | EP14861394.6 | 2014-11-14 | EP3068394A1 | 2016-09-21 | COPP, James Densmore; NEWMAN, Ann W.; LUONG, Anne |
| Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. | ||||||
| 6 | ＲＥＡＲＲＡＮＧＥＤ ＤＵＲＩＮＧ ＴＲＡＮＳＦＥＣＴＩＯＮ（ＲＥＴ）阻害剤としての新規な化合物 | JP2017513448 | 2015-09-10 | JP2017526711A | 2017-09-14 | ムイ、チュン; マイケル、ピー．デマーティノ; ヒラリー、シェンク、アイダム; グアン、ホイピン、エイミー; ドンホイ、チン; チェンデ、ウー; ゴン、ゼン; ヤン、ハイイン; ユ、ハイユ; チャン、ジリウ |
| 本発明は、Rearranged during Transfection(RET)キナーゼの阻害剤である新規な化合物、それらを含有する医薬組成物、それらの製造方法、ならびに消化管過敏性、運動性および/または分泌性および/または腹部障害または疾患の正常化、および/またはRET機能不全に関連するか、または限定されるものではないが、下痢型、便秘型または交互型排便パターン、機能性鼓脹、機能性便秘、機能性下痢、特定不能の機能性腸障害、機能性腹痛症候群、慢性特発性便秘、機能性食道障害、機能性胃十二指腸障害、機能性肛門直腸痛、炎症性腸疾患を含む過敏性腸症候群(IBS);非小細胞肺癌、肝細胞癌、結腸直腸癌、甲状腺髄様癌、濾胞性甲状腺癌、未分化甲状腺癌、甲状腺乳頭癌、脳腫瘍、腹腔癌、固形腫瘍、他の肺癌、頭頸部癌、神経膠腫、神経芽腫、フォンヒッペル−リンドウ症候群および腎臓腫瘍、乳癌、卵管癌、卵巣癌、移行上皮癌、前立腺癌、食道および胃食道接合部の癌、胆管癌、腺癌、および高いRETキナーゼ活性を有する任意の悪性腫瘍などの増殖性疾患の総ての分類を含む、RET活性の変調が治療利益を持ち得る疾患に関する治療のための単独療法または併用療法におけるそれらの使用に関する。 | ||||||
| 7 | 置換サリチルアルデヒド誘導体の合成 | JP2013530310 | 2011-09-22 | JP6031442B2 | 2016-11-24 | ファーマー, ジェイ ジェイ.; ジョブ, ガブリエル イー. |
| 8 | 窒素含有置換基を有するポリマー結合多環式芳香族炭化水素 | JP2014540394 | 2012-10-30 | JP6093988B2 | 2017-03-15 | パスキエ, セシル; ウィス, パトリック |
| 9 | 置換サリチルアルデヒド誘導体の合成 | JP2016207841 | 2016-10-24 | JP2017025096A | 2017-02-02 | ジェイ ジェイ. ファーマー; ガブリエル イー. ジョブ |
| 【課題】サリチルアルデヒド誘導体を合成する方法を提供すること 【解決手段】本発明は、特に、次に示す工程を含む、サリチルアルデヒド誘導体を合成する方法を包含する:a)サリチルアルデヒドまたはその誘導体を提供する工程、b)提供されたサリチルアルデヒド化合物のアンヒドロ二量体を形成する工程、c)アンヒドロ二量体において1以上の化学変換を行う工程、およびd)アンヒドロ二量体を加水分解して、工程(a)で提供されたものと異なるサリチルアルデヒド誘導体を提供する工程。本発明は、新規のサリチルアルデヒド二量体を含む、合成物を提供する。 【選択図】なし |
||||||
| 10 | ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用 | JP2016530958 | 2014-11-14 | JP2016537365A | 2016-12-01 | デンスモア コップ ジェームス; ダブリュー．ニューマン アン; ルオング アンネ |
| {[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ}酢酸を含む固体形態、該固体形態を含む組成物、該固形形態を製造する方法、並びに種々の疾患及び/又は障害の治療のためのそれらの使用方法が本明細書に提供される。【選択図】図1 | ||||||
| 11 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | US16338442 | 2017-09-29 | US20190248729A1 | 2019-08-15 | Min-Kyung LEE; Jin-Kak LEE; Won-Seok HAN |
| This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same. | ||||||
| 12 | Synthesis of substituted salicylaldehyde derivatives | US15155305 | 2016-05-16 | US10040800B2 | 2018-08-07 | Jay J. Farmer; Gabriel E. Job |
| Among other things, the present invention encompasses methods of synthesizing salicylaldehyde derivatives comprising the steps of: a) providing salicylaldehyde or a derivative thereof, b) forming an anhydro dimer of the provided salicylaldehyde compound, c) performing one or more chemical transformations on the anhydro dimer and d) hydrolyzing the anhydro dimer to provide a salicylaldehyde derivative different from that provided in step (a). | ||||||
| 13 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | US15599401 | 2017-05-18 | US09938302B2 | 2018-04-10 | Kyle W. H. Chan; Leah Fung; Robert Sullivan; Paul E. Erdman; Frank Mercurio; Eduardo Torres |
| The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided. | ||||||
| 14 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | US15597671 | 2017-05-17 | US20170333443A1 | 2017-11-23 | Kyle W.H. Chan; Leah Fung; Robert Sullivan; Paul E. Erdman; Frank Mercurio; Eduardo Torres |
| The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided. | ||||||
| 15 | POLYCARBONATE-POLYESTER COMPOSITION AND ARTICLE | US15308678 | 2015-07-08 | US20170190904A1 | 2017-07-06 | Kumar Parimal; Sarah Grieshaber |
| A composition includes specific amounts of a polyester with 1,4 cyclohexanedimethylene terephthalate repeat units, a halogen-free aromatic polycarbonate, a brominated aromatic polycarbonate, and an unsubstituted or substituted C2 C18 hydrocarbyl sulfonate salt. The composition exhibits an improved balance of flame retardancy and transparency relative to a corresponding composition without the sulfonate salt. The composition can be used to fabricate articles that benefit from its transparency and flame retardancy | ||||||
| 16 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | US15155305 | 2016-05-16 | US20160257695A1 | 2016-09-08 | Jay J. Farmer; Gabriel E. Job |
| Among other things, the present invention encompasses methods of synthesizing salicylaldehyde derivatives comprising the steps of: a) providing salicylaldehyde or a derivative thereof, b) forming an anhydro dimer of the provided salicylaldehyde compound, c) performing one or more chemical transformations on the anhydro dimer and d) hydrolyzing the anhydro dimer to provide a salicylaldehyde derivative different from that provided in step (a). | ||||||
| 17 | Substituted Indoles as Selective Protease Activated Receptor 4 (PAR-4) Antagonists | US14820488 | 2015-08-06 | US20160083363A1 | 2016-03-24 | Heidi E. Hamm; Shaun R. Stauffer; Craig W. Lindsley; Wandong Wen; Summer E. Young; Matthew T. Duvernay; Kayla J. Temple |
| Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition. | ||||||
| 18 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | US14496514 | 2014-09-25 | US20150011761A1 | 2015-01-08 | Jay J. Farmer; Gabriel E. Job |
| Among other things, the present invention encompasses methods of synthesizing salicylaldehyde derivatives comprising the steps of: a) providing salicylaldehyde or a derivative thereof, b) forming an anhydro dimer of the provided salicylaldehyde compound, c) performing one or more chemical transformations on the anhydro dimer and d) hydrolyzing the anhydro dimer to provide a salicylaldehyde derivative different from that provided in step (a). | ||||||
| 19 | ELECTRONICALLY CONDUCTIVE POLYMER BINDER FOR LITHIUM-ION BATTERY ELECTRODE | US13615402 | 2012-09-13 | US20130253163A1 | 2013-09-26 | Gao Liu; Shidi Xun; Vincent S. Battaglia; Honghe Zheng; Mingyan Wu |
| A family of carboxylic acid groups containing fluorene/fluorenon copolymers is disclosed as binders of silicon particles in the fabrication of negative electrodes for use with lithium ion batteries. Triethyleneoxide side chains provide improved adhesion to materials such as, graphite, silicon, silicon alloy, tin, tin alloy. These binders enable the use of silicon as an electrode material as they significantly improve the cycle-ability of silicon by preventing electrode degradation over time. In particular, these polymers, which become conductive on first charge, bind to the silicon particles of the electrode, are flexible so as to better accommodate the expansion and contraction of the electrode during charge/discharge, and being conductive promote the flow battery current. | ||||||
| 20 | 電荷制御剤及びそれを用いたトナー | JP2013523427 | 2013-01-30 | JPWO2013129015A1 | 2015-07-30 | 育夫 木村; 一徳 辻; 雅也 東條; 昌史 浅貝 |
| 本発明は、下記一般式(1)で表されるピリジンジカルボン酸誘導体の1種又は2種以上を有効成分として含有する電荷制御剤を提供する。【化1】[一般式(1)中、R1、R2及びR3は相互に同一でも異なってもよく、水素原子等を示し、R4及びR5は相互に同一でも異なってもよく、水素原子等を示し、R6及びR7は相互に同一でも異なってもよく、置換基を有していてもよい炭素原子数5〜10のシクロアルキル基、置換若しくは無置換の芳香族炭化水素基、又は置換若しくは無置換の縮合多環芳香族基を示す。R1、R2及びR3は、隣り合う基同士で互いに結合して環を形成していてもよい。] | ||||||
QQ群二维码
意见反馈
意见反馈